Celling Technologies and SpineSmith team up to research adipose tissue derived stem cell applications

Nov 10 2009

Celling Technologies, a subsidiary of SpineSmith Partners, is collaborating with Tissue Genesis, Inc. to research potential applications for adipose tissue derived adult stem cells. SpineSmith acquired the global rights in spine for Tissue Genesis' adipose (fat) tissue derived stem cell technology in November of 2007. Replacing the prior arrangement, this new exclusive agreement allows Celling Technologies to further research adipose tissue derived stem cells in a variety of human applications, including orthopedics, vascular, trauma, plastics and disease, in certain agreed upon medical institutes.

Celling's team of scientists will collaborate with Tissue Genesis, and its licensees, to research adipose tissue derived stem cell applications at certain medical institutions throughout the world. "We believe adult stem cells will revolutionize modern medicine, and our business development efforts are positioning the company to continue leading the research and development of cellular therapy. The agreement with Tissue Genesis solidifies our position as a leader, and continues to build the opportunity for surgeons and institutions interested in the future of regenerative medicine," says Kevin Were, Director of Business Development for Celling Technologies.

This agreement allows Celling Technologies to offer Tissue Genesis' technology into its expanding network of surgeons and facilities around the world. The Regenerative Institute platform allows for collaboration between scientists, engineers and surgeons to drive research validating the efficacy of these adult stem cell therapies. "We believe our agreement with Celling Technologies gives Tissue Genesis a unique relationship to expand research with our Cell Isolation System technology, and collaborating with scientists and physicians," says Anton Krucky, CEO of Tissue Genesis.

The Tissue Genesis Cell Isolation System rapidly processes (in about an hour) autologous (patient-derived) adipose tissue and concentrates large quantities of regenerative cells (including adult stem cells) at point of care. This technology matches well with the current SpineSmith product portfolio of surgical implants and the current cell therapy products being investigated by Celling Technologies.